Navigation Links
nContact's Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012
Date:1/9/2012

MORRISVILLE, N.C., Jan. 9, 2012 /PRNewswire/ -- nContact, Inc., the leading innovator in epicardial ablation devices, today announced its technology will be presented by physicians in two posters at the 17th Annual International Boston Atrial Fibrillation Symposium, January 12-14 in Boston, Massachusetts.  nContact will be showcasing its Numeris® Coagulation System with VisiTrax® and next generation EPi-Sense™ Coagulation System at its Boston AF Symposium booth #301.

nContact's epicardial ablation device integrates suction, perfusion and radiofrequency energy to ensure consistent cardiac tissue contact and create visible, continuous lesions on the epicardium of a beating heart. Access to the posterior of the atrium is achieved with unique access through the diaphragm with a SUBTLE (sub-thoracic, total endoscopic) approach for minimally invasive, closed-chest epicardial ablation.  

The technology will be presented in the following posters on Friday, January 13, 2012 available from 7:30 am until 6:30 pm:

  • Poster # 10 titled: "Prospective Reveal® XT Outcomes for the Convergent Atrial Fibrillation Ablation Procedure"
    Evaluates long-term outcomes of a multidisciplinary ablation procedure to treat persistent or longstanding persistent AF, as monitored by Reveal XT technology (Medtronic); presented by Borut Gersak, MD, of University Medical Center Ljubljana, Ljubljiana, Slovenia.
  • Poster #20 titled: "Multicenter Retrospective Outcomes for the Treatment of Atrial Fibrillation Using the Multidisciplinary Convergent Procedure"
    Examines outcomes of closed chest AF ablation procedure on patients with persistent or longstanding persistent AF across four U.S. sites; presented by Dr. Keith Golden of St. Vincent Hospital, Indianapolis, IN.
  • About nContact, Inc.
    nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, continuous, bi-atrial lesions on the epicardium of a beating heart.

    To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures.

    The Numeris™ and EPi-Sense™ Coagulation Systems with VisiTrax® have CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter. For more information, please visit www.ncontactinc.comMedia Contacts

     Beth Rose

    Kimberly MuscaranContact, Inc

    The Ruth Group T (919)655-1566 

    T (646) 536-7011brose@ncontactinc.com

    kmuscara@theruthgroup.com


    '/>"/>
    SOURCE nContact, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Ikaria® Commences Global Registration Trial for Bioabsorbable Cardiac Matrix
    2. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
    3. Australias Sporting Clubs Select Cardiac Science AEDs
    4. Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument
    5. MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries
    6. Philips Launches HeartStart FR3 Automated External Defibrillator for Professional Responders Treating Victims of Sudden Cardiac Arrest
    7. MedSolutions Announces Program to Reduce Unnecessary Implantable Cardiac Defibrillator Surgeries
    8. Cardiac Dimensions Announces Presentation of Two-Year Efficacy Data From TITAN Clinical Trial
    9. Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
    10. "Today" Show, "Fox & Friends" Put Spotlight on Sudden Cardiac Arrest
    11. Cardiac Dimensions® Receives CE Mark Approval for Enhanced CARILLON® Mitral Contour System™
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
    (Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
    (Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
    Breaking Medicine Technology:
    (Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
    (Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
    (Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
    (Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
    Breaking Medicine News(10 mins):